Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,757 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Dexamethasone, Aspirin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more

Conditions: Palmoplantar Keratoderma
Interventions: Tapinarof; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Insomnia
Interventions: BBTI-MV, Information Control; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Neoplasm, Colorectal Cancer
Interventions: Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Hyperphosphatemia
Interventions: Tenapanor, Placebo, Phosphate Binder Agents; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 48
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more

Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Interventions: Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound; Procedure · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 5
States / cities: Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more

Conditions: Metastatic Melanoma, Skin Cancer
Interventions: Ipilimumab, Nivolumab, Cryoablation; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Refractory Acute Leukemia, Pediatric Relapsed
Interventions: Ziftomenib, Venetoclax, Azacitidine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leptomeningeal Metastases
Interventions: Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP; Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 99 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: PRIME, COMBO; Other
Lead sponsor: University of Virginia; Other
Eligibility: 65 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol); Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 18
States / cities: Clovis, California • Duarte, California • Los Angeles, California + 14 more

Conditions: Food Hypersensitivity
Interventions: Peanut SLIT, Placebo SLIT; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Rheos® Baroreflex Hypertension System; Device
Lead sponsor: CVRx, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more

Conditions: Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Interventions: sodium phenylbutyrate; Drug
Lead sponsor: Westat; Other
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Stanford, California • St Louis, Missouri • New York, New York + 2 more

Conditions: Germ Cell Tumor
Interventions: Bleomycin (active name: Bleomycin Sulfate), Etoposide, Cisplatin, Pegylated G-CSF (Pegfilgrastim), Filgrastim; Drug
Lead sponsor: University of Sydney; Other
Eligibility: 11 Years to 50 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 21
States / cities: Downey, California • Loma Linda, California • Long Beach, California + 15 more

Conditions: Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions: ON 01910.Na; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Cancer
Interventions: Induction Chemotherapy - FOLFIRINOX, Induction Chemotherapy - Gemcitabine and Nab-Paclitaxel, MR-LINAC Guided Radiotherapy, Surgical Exploration and Resection; Drug · Radiation · Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity, Weight Loss, Sedentary Lifestyle
Interventions: Weight loss, Exercise, Sitless; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years to 85 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Extracorporeal Membrane Oxygenation Complication
Interventions: ECMO-free protocol, Usual Care; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: San Diego, California • Stanford, California • Minneapolis, Minnesota + 4 more

Conditions: Heart Failure, Diastolic
Interventions: Exercise Training; Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 60 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Sleep Disturbance, Insomnia, Acute Coronary Syndrome
Interventions: BLT Intervention, BLB Intervention, Sleep Hygiene Education; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
Interventions: Homoharringtonine, Imatinib Mesylate; Drug
Lead sponsor: ChemGenex Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus in Pregnancy
Interventions: SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nicotine Dependence
Interventions: Selegiline Transdermal Patch, Placebo, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: College Park, Maryland • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more

Search by objective public record fields.

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 2 (BBTIMVII)

New Individualized Therapy Trial for Metastatic Colorectal Cancer

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Cryoablation+Ipilimumab+Nivolumab in Melanoma

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

A Study of Sublingual Immunotherapy in Peanut-allergic Children

Rheos® Pivotal Trial

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer

Empowered With Movement to Prevent Obesity and Weight Regain

The ECMO-Free Trial

Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients

The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

Selegiline for Smoking Cessation - 1